Effect of RAS Blockers on CKD Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 106 participants.
Also called NCT03195023
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 106 participants
- Registry
-
NCT03195023
-
- Other papers using this trial's data
- Renin-angiotensin-aldosterone system blockers effect in chronic kidney disease progression in hypertensive elderly patients without proteinuria: PROERCAN trial
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Spain
- Registry status
- Unknown status
Technical summary
Registry record NCT03195023. Randomized; no masking; primary purpose treatment. Start 2015-06 (registry gives no type); primary completion 2019-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of RAS Blockers on CKD Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01)
- Acronym
- PROERCAN01
- Condition
- Renal Insufficiency, Chronic
- Condition
- Proteinuria
- Intervention (Drug)
- Lisinopril
- Intervention (Drug)
- Amlodipine
- Lead sponsor
- Hospital General Universitario Gregorio Marañon
Record details
- Record id
cardio:ct-nct03195023- Content hash
e867ff4d0389b2d4087ff0d4f09a26c048223c09d95e19d346181c046133cdcc